News Focus
News Focus
icon url

thermo

05/23/22 7:49 PM

#477715 RE: skitahoe #477710

(It's nuanced) Previous or Planned Meeting Presentation or Release of Information

Meeting presentation: A complete manuscript submitted to the journal following or prior to presentation at a scientific meeting or publication of preliminary findings elsewhere (ie, as an abstract) is eligible for consideration for publication. Authors considering presenting or planning to present the work at an upcoming scientific meeting should indicate the name and date of the meeting on the manuscript submission form. For accepted papers, the editors may be able to coordinate publication with the meeting presentation. Authors of submitted papers, including those accepted but not yet published, should not disclose the status of such papers during such meeting presentations that occur before the work is published. Authors who present information contained in a manuscript that is under consideration by this journal during scientific or clinical meetings should not distribute complete reports (ie, copies of manuscripts) or full data presented as tables and figures to conference attendees or journalists. Publication of abstracts in print and online conference proceedings, as well as posting of slides or videos from the scientific presentation on the meeting website, is acceptable. However, for manuscripts under consideration by this journal, publication of full reports in meeting proceedings or online, issuing detailed news releases reporting the results of the study that go beyond the meeting abstract, or participation in formal news conferences will ordinarily jeopardize chances for publication of the submitted manuscript in this journal.5 Media coverage of presentations at scientific meetings will not jeopardize consideration, but direct release of information through press releases or news media briefings may preclude consideration of the manuscript by this journal.5 Rare instances of papers reporting public health emergencies should be discussed with the editor. Authors submitting manuscripts or letters to the editor regarding adverse drug or medical device reactions, reportable diseases, etc, should also report this information to the relevant government agency.
icon url

X Master

05/23/22 9:26 PM

#477733 RE: skitahoe #477710

Gary, how do you know “ We know that Dr. Liau is achieving superior results at UCLA with the inclusion of drugs like Keytruda”
icon url

Lykiri

05/24/22 7:37 AM

#477875 RE: skitahoe #477710

I frankly still cannot see what has happened with the Top 100 patients both Dr. Liau and Ashkan have discussed, perhaps the Journal will clarify why more of them aren't seen in the K-M plots.



Gary,
The Top 100 are the patients of the ITT cohort (n=331) still alive 31,5 months from randomization. (34,5 months from surgery)

43 mMGMT DCVax-L patients
18 unMGMT DCVax-L patients
1 unknown MGMT DCVax-L patient
38 placebo patients.

Around 50% (n=30) of those DCVax-L patients (n=62) are still alive 60 months from randomization.(63 months from surgery)